Literature DB >> 16216995

High attributable risk of elevated C-reactive protein level to conventional coronary heart disease risk factors: the Third National Health and Nutrition Examination Survey.

Michael Miller1, Min Zhan, Stephen Havas.   

Abstract

BACKGROUND: C-reactive protein (CRP), a marker of systemic inflammation, is predictive of coronary heart disease (CHD) events. However, the extent to which high CRP levels (>3 mg/L) may be attributable to high cholesterol levels and other CHD risk factors has not been well defined.
METHODS: The prevalence of high CRP levels in the third National Health and Nutrition Examination Survey (n = 15 341) was studied using CHD risk-factor cut points designated as abnormal (total cholesterol values, >or=240 mg/dL [>or=6.22 mmol/L]; fasting blood glucose levels, >or=126 mg/dL [>or=6.99 mmol/L]; blood pressure, >or=140/90 mm Hg; body mass index [BMI], >or=30 kg/m(2); high-density lipoprotein cholesterol values, <40 mg/dL [<1.04 mmol/L] for men and <50 mg/dL [<1.30 mmol/L] for women; triglyceride levels, >or=200 mg/dL [>or=2.26 mmol/L]; current smoking status) or borderline (total cholesterol values, 200-239 mg/dL [5.18-6.19 mmol/L]; fasting blood glucose levels, 100-125 mg/dL [5.55-6.94 mmol/L]; blood pressure, 120-139/80-89 mm Hg; BMI, 25.0-29.9 kg/m(2), and triglyceride values 150-199 mg/dL [1.70-2.25 mmol/L], former smoking status), or normal.
RESULTS: Weighted multiple logistic regression analysis demonstrated that high CRP level was significantly more common with obesity (odds ratio [OR], 3.78; 95% confidence interval [CI], 3.28-4.35]), overweight (OR, 1.88; 95% CI, 1.62-2.18), and diabetes (OR, 1.91; 95% CI, 1.54-2.38) and that high CRP level was rare in the absence of any borderline or abnormal CHD risk factor in men (4.4%) and women (10.3%). Overall, the risk of elevated CRP level attributable to the presence of any abnormal or borderline CHD risk factor was 78% in men and 67% women.
CONCLUSIONS: These data suggest that elevated CRP levels in the general population are in large measure attributable to traditional CHD risk factors. Moreover, CRP level elevation is rare in the absence of borderline or abnormal risk factors. As such, CRP measurements may have limited clinical utility as a screening tool beyond other known CHD risk factors.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16216995     DOI: 10.1001/archinte.165.18.2063

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  40 in total

1.  Ischaemic heart disease--a new issue in cystic fibrosis?

Authors:  Felicity M R Perrin; Walter Serino
Journal:  J R Soc Med       Date:  2010-07       Impact factor: 5.344

2.  Canadian Cardiovascular Society position statement--recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease.

Authors:  Ruth McPherson; Jiri Frohlich; George Fodor; Jacques Genest
Journal:  Can J Cardiol       Date:  2006-09       Impact factor: 5.223

3.  Increased systemic elastase and C-reactive protein in aggressive periodontitis (CLOI-D-00160R2).

Authors:  Martin Wohlfeil; Susanne Scharf; Yasemin Siegelin; Beate Schacher; Gerhard M Oremek; Hildegund Sauer-Eppel; Ralf Schubert; Peter Eickholz
Journal:  Clin Oral Investig       Date:  2011-10-19       Impact factor: 3.573

4.  White blood cell global methylation and IL-6 promoter methylation in association with diet and lifestyle risk factors in a cancer-free population.

Authors:  Fang Fang Zhang; Regina M Santella; Mary Wolff; Maya A Kappil; Steven B Markowitz; Alfredo Morabia
Journal:  Epigenetics       Date:  2012-06-01       Impact factor: 4.528

5.  APOC3 promoter polymorphisms C-482T and T-455C are associated with the metabolic syndrome.

Authors:  Michael Miller; Jeffrey Rhyne; Hegang Chen; Valerie Beach; Richard Ericson; Kalpana Luthra; Manjari Dwivedi; Anoop Misra
Journal:  Arch Med Res       Date:  2007-03-26       Impact factor: 2.235

6.  Inflammatory proteins on HDL: what are we measuring?

Authors:  Kevin D O'Brien
Journal:  Transl Res       Date:  2007-05-21       Impact factor: 7.012

Review 7.  Long-chain n-3 polyunsaturated fatty acids: new insights into mechanisms relating to inflammation and coronary heart disease.

Authors:  Baukje de Roos; Yiannis Mavrommatis; Ingeborg A Brouwer
Journal:  Br J Pharmacol       Date:  2009-05-05       Impact factor: 8.739

8.  Low-dose nonlinear effects of smoking on coronary heart disease risk.

Authors:  Louis Anthony Tony Cox
Journal:  Dose Response       Date:  2011-10-14       Impact factor: 2.658

9.  Safety and Impact of Low-dose Methotrexate on Endothelial Function and Inflammation in Individuals With Treated Human Immunodeficiency Virus: AIDS Clinical Trials Group Study A5314.

Authors:  Priscilla Y Hsue; Heather J Ribaudo; Steven G Deeks; Tanvir Bell; Paul M Ridker; Carl Fichtenbaum; Eric S Daar; Diane Havlir; Eunice Yeh; Ahmed Tawakol; Michael Lederman; Judith S Currier; James H Stein
Journal:  Clin Infect Dis       Date:  2019-05-17       Impact factor: 9.079

Review 10.  Novel markers of inflammation in atherosclerosis.

Authors:  Salim S Virani; Venkateshwar R Polsani; Vijay Nambi
Journal:  Curr Atheroscler Rep       Date:  2008-04       Impact factor: 5.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.